Navigation Links
3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
Date:8/15/2011

MENLO PARK, Calif., Aug. 15, 2011 /PRNewswire/ -- 3-V Biosciences, Inc. announced today the appointment of George W. Kemble, PhD as Chief Scientific Officer.

(Logo:  http://photos.prnewswire.com/prnh/20100513/LA04336LOGO)

"We are very pleased to have George as the newest member of the 3-V senior management team," said Merdad V. Parsey, MD, PhD, 3-V's Chief Executive Officer.  "George's extensive experience in drug discovery and development, as well as virology and host-cell biology, brings additional strength to the 3-V team and will further our efforts in this novel area."

Prior to joining 3-V Biosciences, Dr. Kemble was with MedImmune, Inc., a subsidiary of Astra-ZenecaPLC, where he most recently served as Senior Vice President of R&D and Head of Research.  During his tenure, Dr. Kemble was responsible for the research and development of multiple products, including the successful launch of FluMist®, the first innovation in influenza vaccines in over 60 years.  The research organization for which he was responsible included over 700 scientists in Maryland, California and Cambridge, England, with expertise in research biology, lead generation and translational science in the areas of infectious diseases, oncology, inflammatory, respiratory, autoimmune diseases, neuroscience, cardiovascular and gastrointestinal indications.  Dr. Kemble began his research career as a staff scientist at Aviron, which was later acquired by MedImmune.  Dr. Kemble received a BS from the University of Santa Clara and a PhD from Stanford University and did his post-doctoral training at UCSF, where he worked on a number of different human viruses.

"I'm very excited by the important projects we have in front of us," said Dr. Kemble.  "Our approach to combating these pathogens is highly innovative, and I am looking forward to continuing to grow our organization's expertise at developing these impactful medicines."  

About 3-V Biosciences3-V Biosciences, Inc. is a privately-held biopharmaceutical company dedicated to discovering, developing and ultimately commercializing novel antiviral therapeutics that target host cell factors required for viral infection, thereby avoiding many of the shortcomings of traditional pathogen-directed approaches.  The company is located in Menlo Park, California and is financed by The Column Group, Kleiner Perkins Caufield&Byers, and New Enterprise Associates.

For additional information on 3-V Biosciences, please visit www.3vbio.com.Contact informationStephen R. BradyChief Business Officer650-561-8600
'/>"/>

SOURCE 3-V Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... ... as well as to their processing and transport properties. With the Litesizer™ ... variety of samples. The Litesizer™ 100 gives rapid and accurate insight into particle ...
(Date:2/28/2017)... , ... February 28, 2017 , ... FireflySci is a ... Starting out in late 2014, FFS had a mission to bring affordable and quality ... released another mega product that gives a lab everything needed to get started with ...
(Date:2/28/2017)... MA (PRWEB) , ... February 28, 2017 , ... ... clinical trials, yet requires extensive coordination and expertise. Colpitts Clinical Trial Travel ... celebrating 15 years of meeting this unique need within the biotechnology and pharmaceutical ...
(Date:2/28/2017)... ... 2017 , ... RoviSys, a leading independent provider of comprehensive ... the Cisco® Digital Solutions Integrator Program. As a member of this new program, ... Industrial IT and Business IT in manufacturing environments. , John Cunningham, Director, ...
Breaking Biology Technology:
(Date:2/28/2017)...  EyeLock LLC, ein marktführendes Unternehmen im Bereich ... Lösung zur Iris-Erkennung auf der neuesten Mobilplattform ... dem Mobile World Congress 2017 (27. Februar ... 3, Stand 3E10, vorstellen. Der ... – eine Kombination aus Hardware, Software und ...
(Date:2/27/2017)... 2017   Strategic Cyber Ventures , the industry,s ... a $3.5 million investment in  Polarity , the first ... is DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran ... this series A round of funding. This new funding ...
(Date:2/26/2017)... Feb. 25, 2017  Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring, announces ... Reentry. "Too often, too many offenders ... county jails are trying to tackle this ongoing ... friends and family members. While significant steps are underway, ...
Breaking Biology News(10 mins):